Effectiveness | SoC | VN | Difference |
---|---|---|---|
Blindness-free yearsa | 20.65 | 28.32 | 7.67 |
Quality-adjusted survival (QALYs) | 11.62 | 18.35 | 6.73 |
Costs | |||
VN treatment | 0 | 768’087 | 768’087 |
Eligibility testing (viable retinal cells) | 0 | 493 | 493 |
Adverse events | 0 | 768 | 768 |
Health care resource useb | 137’252 | 132’305 | -4’947 |
Total costs, healthcare system perspective | 137’252 | 901’654 | 764’402 |
Incremental cost effectiveness, health care system perspective (base case) | |||
ICER (CHF per blindness-free year gained)a | 99,603 | ||
ICER (CHF per QALY gained) | 113’526 |